Takeda Pharmaceutical Company Limited (TAK) — Stock Price, Chart & Analysis
Takeda Pharmaceutical Company Limited (TAK) is a Healthcare stock currently trading at $18.95, up 0.32% on the day. It carries a market capitalization of $60.52B. Over the past 52 weeks, TAK has traded between $12.99 and $19.10. Takeda Pharmaceutical Company Limited pays a dividend yielding 3.3%. View the live TAK chart, technical opinion, analyst ratings, fundamentals and latest news below.
Takeda Pharmaceutical Company Limited (TAK) key data
| Price | $18.95 |
| Change (today) | +0.32% |
| Previous close | $18.89 |
| Market cap | $60.52B |
| EPS (TTM) | $-0.33 |
| Dividend yield | 3.3% |
| 52-week high | $19.10 |
| 52-week low | $12.99 |
| Beta | 0.10 |
| Avg. volume | 3.10M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Frequently asked questions about Takeda Pharmaceutical Company Limited (TAK)
How much does one share of Takeda Pharmaceutical Company Limited cost?
As of the latest update, one share of Takeda Pharmaceutical Company Limited (TAK) trades at $18.95 (+0.32% today).
What is Takeda Pharmaceutical Company Limited's market cap?
Takeda Pharmaceutical Company Limited has a market capitalization of approximately $60.52B.
What is Takeda Pharmaceutical Company Limited's earnings per share (EPS)?
Takeda Pharmaceutical Company Limited's trailing twelve-month EPS is $-0.33.
Does Takeda Pharmaceutical Company Limited pay a dividend?
Yes — Takeda Pharmaceutical Company Limited pays a dividend with a yield of 3.3% ($0.62 per share annually).
What is Takeda Pharmaceutical Company Limited's 52-week trading range?
Over the past year, TAK has traded between $12.99 and $19.10.
What is the analyst price target for Takeda Pharmaceutical Company Limited?
The mean analyst price target for Takeda Pharmaceutical Company Limited is $21.99. This is informational only and not investment advice.
Latest Takeda Pharmaceutical Company Limited (TAK) news
- Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026News · Sep 22, 2026
- Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health SystemsNews · Sep 18, 2026
- Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?News · Sep 17, 2026
- U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ExpectationsNews · Sep 14, 2026
- Andy Plump, architect of Takeda’s R&D overhaul, to retire next yearNews · Sep 10, 2026
- Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026News · Sep 9, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live TAK dashboard…